71 results
8-K
EX-99.2
COGT
Cogent Biosciences Inc
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
at baseline; (1) no post-baseline assessment Data as of: 26Oct2022 DeAngelo D,. et al. American Society of Hematology (ASH) 2022 Annual Meeting; New … : no post-baseline assessment available 77% achieved complete clearance of mast cell aggregates by central review – KIT D816V VAF 92% of patients
8-K
EX-99.1
COGT
Cogent Biosciences Inc
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am
assessment of patient response
Developed an optimized formulation of bezuclastinib with new dosage strength and over 40% improvement in clinical … assessment, in addition to pharmacokinetic and safety data. Cogent will host an investor webcast on December 12, 2022 at 8:00 am ET to discuss these data
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 Jan 19
Regulation FD Disclosure
8:02am
profile
ACTR + Rituximab Trial Design Cycles 4+ Rituximab q21 days Response Assessments q42 days Cycle 3 Rituximab 1st Response Assessment DLT Assessment … potential Next Steps ACTR707 + rituximab (ATTCK-20-03, Phase 1) Complete Dose Level 3 safety evaluation and assessment Cohort expansion at recommended phase 2
424B5
COGT
Cogent Biosciences Inc
30 Nov 20
Prospectus supplement for primary offering
5:28pm
or golden parachute arrangements; and
exemption from the auditor attestation requirement in the assessment of our internal control over financial … any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans
424B5
COGT
Cogent Biosciences Inc
2 Dec 20
Prospectus supplement for primary offering
5:06pm
attestation requirement in the assessment of our internal control over financial reporting.
We may take advantage of these exemptions for up to five years … risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted
8-K
EX-10.1
kqujte
9 Jul 21
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-99.1
dewk0 9bhdedfvcmtju
3 Dec 18
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting
7:50am
8-K
EX-99.2
bqjw4rplb7dz2mob1xxm
3 Dec 18
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting
7:50am
8-K
EX-99.1
xvr2k m1qvs
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
60jnn 8bpbgarc2
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
8-K
EX-99.1
wnb6j6m7 kekeq12
4 Nov 19
Unum Therapeutics Announces Strategic Focus on DevelopingBest-in-Class
4:13pm
8-K
EX-99.1
rsv0na46 8ev
13 May 19
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
7:10am
8-K
EX-99.1
2bdw2wk0 pv02xf57ra
13 Nov 18
Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
9:03am
8-K
EX-99.1
osrq5zxoeva35as
28 Mar 19
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
7:12am
8-K
EX-99.1
g6tkl
12 Aug 19
Unum Therapeutics Reports Second Quarter 2019 Financial Results
4:12pm
8-K
EX-99.1
hma22 4tj
7 Mar 19
Regulation FD Disclosure
2:02pm